2018 Speaker Lineup

• April Abbott, PhD, D(ABMM), Director, Microbiology, Deaconess Health System
• Neeraj Adya, PhD, Director, Pharmacodiagnostics Translational Medicine, Bristol-Myers Squibb
• Jeffrey N. Agar, PhD, Associate Professor, Chemistry and Pharm. Sci., Northeastern University
• Jeff Allen, PhD, President, CEO, Friends of Cancer Research
• Jim Almas, MD, Medical Director, MolDX, PalmettoGBA
• Timothy Amukele, MD, PhD, Assistant Professor of Pathology, Johns Hopkins University School of Medicine
• Orly Ardon, MSc, MBA, PhD, R&D Program Manager, ARUP Laboratories/University of Utah
• Deepti Aurora-Garg, PhD, Director, Companion Diagnostics, Translational Medicine, Merck & Co.
• Esther Babady, PhD, Director, Clinical Microbiology Operations, Memorial Sloan Kettering Cancer Center
• Jonathan Baden, MS, Director, Pharmacodiagnostics, Translational Medicine, Bristol-Myers Squibb
• Tricia A. Bal, MD, MBA, Oncology Biomarkers and Diagnostics Leader, Director, Oncology Global Medical Affairs, Merck
• Ziv Bar-Joseph, PhD, FORE Systems Professor of Computational Biology and Machine Learning, Computational Biology, Carnegie Mellon University
• J. Carl Barrett, PhD, Vice President, Translational Sciences, Onc iMed, AstraZeneca
• Haim H. Bau, PhD, Professor, Mechanical Engineering and Applied Mechanics, University of Pennsylvania
• Aparna B. Baxi, Graduate Student, Chemistry & Biochemistry, Anatomy and Regenerative Biology, University of Maryland–College Park, George Washington University
• Holger Becker, PhD, Founder & CSO, microfluidic ChipShop GmbH
• Jonathan Beer, MBA, Director, Lead of Disruptive Technologies, Novartis Oncology
• Suzanne Belinson, PhD, Executive Director of Clinical Markets, Blue Cross Blue Shield Association
• Ryma Benayed, PhD, Technical Director, Clinical Next Generation Sequencing Laboratory, Assistant Attending, Pathology, Memorial Sloan Kettering Cancer Center
• Michael Berger, PhD, Associate Director, Marie Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
• Annerose Berndt, Vice President, Clinical Genomics, Clinical Genomics, UPMC
• Jason Bhan, MD, CMO & Co-Founder, Prognos
• Tim Blauwkamp, PhD, CSO, Karius
• Kelly Bolton, MD, Hematology-Oncology Fellow, Department of Medicine, Memorial Sloan Kettering
• Suman Bose, PhD, Postdoctoral Fellow, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
• Eric Button, MSc, MBA, President & Managing Director, NeoMark Ventures
• Timothy Cannon, MD, Clinical Director, Inova Schar Cancer Institute; Assistant Professor, Virginia Commonwealth University
• W. Kevin Carpenter, CTO, Porticos
• Cesar Castro, MD, Director, Cancer Program, MGH Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School
• Joseph Chin, MD, MS, Deputy Director, Coverage and Analysis Group, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services (CMS)
• Charles Chiu, MD, PhD, Associate Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine
• Dipanjan Chowdhury, PhD, Chief of the Division of Radiation and Genomic Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School; Associate Member, Broad Institute of Harvard & MIT
• Jason Christiansen, Vice President of Diagnostics, Ignyta
• Melina Cimler, PhD, CEO & Founder, PandiaDx
• William Clarke, PhD, MBA, DABCC, Associate Professor of Pathology, Johns Hopkins University School of Medicine
• Carolyn Compton, MD, PhD, Professor of Life Sciences, School of Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Department of Pathology, Mayo Clinic School of Medicine
• Richard J. Cote, MD, FRCPath, FCAP, Professor, Joseph R. Coulter Jr. Chair, Pathology & Laboratory Medicine; Professor, Biochemistry and Molecular Biology; Chief of Pathology, Jackson Memorial Hospital
• Massimo Cristofanilli, MD, FACP, Professor, Medicine; Associate Director, Translational Research and Precision Medicine; Director, OncoSET Precision Medicine Program, Medicine-Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
• Mark Curran, PhD, Vice President, Companion Diagnostics, Janssen R&D
• Robert D. Daber, PhD, Founder and CEO, Gnosity Consults
• Meghna Das Thakur, PhD, Scientist, Oncology Biomarker Development, Genentech
• John Deeken, MD, COO, Inova Translational Medicine Institute, Senior Vice President, Inova Health System; Associate Professor, Virginia Commonwealth University
• Manish Deshpande, PhD, Vice President, R&D, Point of Care BU, Siemens Healthcare
• Don L. DeVoe, PhD, Professor, Mechanical Engineering, University of Maryland, College Park
• Alex DeWinter, PhD, Managing Director, GE Ventures
• Luis A. Diaz, MD, Head, Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Conference Chairman
• Maximilian Diehn, MD, PhD, Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford University
• Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children’s Hospital Los Angeles; Assistant Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
• Dennis J. Dietzen, PhD, DABCC, FAACC, President, AACC; Professor of Pathology & Immunology and Pediatrics, Washington University School of Medicine; Medical Director of Laboratory Services, St. Louis Children’s Hospital
• Minh Doan, MD, PhD, Assay Developer, Imaging Platform, Broad Institute
• Eric F. Donaldson, PhD, Clinical Virology Reviewer, Co-Chair of the FDA Genomics Working Group Division of Antiviral Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration
• Zigang Dong, PhD, Executive Director & Professor, Cellular & Molecular Biology, The Hormel Institute, University of Minnesota
• Shivang Doshi, MSc, Director, Boston Healthcare Associates
• Nicholas Dracopoli, PhD, Senior Vice President, Translational Science at Personal Genome
• Lynn G. Dressler, PhD, Director, Personalized Medicine and Pharmacogenomics, Mission Health
• Robert Dumanois, Manager, Reimbursement Strategy, Thermo Fisher Scientific
• Karen W. Dyer, MT(ASCP), DLM, Director, Division of Clinical Laboratory Improvement and Quality, Centers for Medicare & Medicaid Services
• Mark Edinger, Scientific Affairs Director, Flow Cytometry, Q2 Solutions
• Kenneth Emancipator, MD, Executive Medical Director and Head of Companion Diagnostics, Translational Medicine, Merck
• Rachel Evans, CMO, Family Medicine, Henry J. Austin Health Center
• Seth A. Faith, PhD, Research Leader, CBRNE Defense/Applied Genomics, Battelle
• Emily Farrow, PhD, CGC, Associate Professor, UMKC School of Medicine, Director of Laboratory, Operations Center for Pediatric Genomic Medicine, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics
• Marta Fernandez Suarez, Daktari Diagnostics & FIND
• Joseph V. Ferrara, MS, CEO, Boston Healthcare Associates
• Adam Garver, MFS, Forensic Scientist – CODIS, Office of Ohio Attorney General
• Sandra Gaston, PhD, Director, Molecular Biomarkers Research Laboratory, Pathology and Laboratory Medicine, Tufts Medical Center
• Joshy George, PhD, Associate Director, Computational Sciences, Jackson Laboratory for Genomic Medicine
• Ionita Ghiran, MD, Associate Professor of Medicine, Beth Israel Deaconess Medical Center
• Soma Ghosh, PhD, Scientific Reviewer, CDRH, FDA
• Harry Glorikian, MBA, Healthcare Consultant
• Jim Goldberg, MD, Chief Medical Officer, Myriad Women's Health
• Stuart Goldberg, MD, Chief Scientific Officer, COTA Inc
• Alberto Gutierrez, PhD, Consultant, Former Director, Office of In Vitro Diagnostics and Radiological Health, FDA
• Todd Haim, PhD, Program Director, National Cancer Institute SBIR Development Center
• Sam M. Hanash, MD, PhD, Professor, Molecular Pathology, Division of Pathology Lab Medicine, The University of Texas MD Anderson Cancer Center
• Amanda Harrington, PhD, Associate Professor, Pathology; Medical Director, Microbiology, Loyola University Medical Center
• Robert Havasy, MS, Senior Director, HIS, HIMSS North America
• Matthew Hawryluk, PhD, Executive Vice President and Chief Business Officer, Gritstone Oncology
• Carolyn Hiller, Program Director, Clinical Diagnostics, Medical Device Innovation Consortium
• Hayden Huang, Senior Engineer, Center for Science, Technology and Engineering, Government Accountability Office
• Stephen Hull, Founder and Principal, Hull Associates LLC.
• Hatim Husain, MD, Physician, Medical Oncology, University of California, San Diego
• Hyungsoon Im, PhD, Assistant Professor, Center for Systems Biology, Massachusetts General Hospital
• Gail Javitt, Member of the Firm, Health Care & Life Sciences, Epstein Becker & Green, P.C.
• Sidhant Jena, MBA, Co-Founder & CEO, Jana Care
• Yuan Ji, PhD, DABCP, DABMGG, FACMG, Assistant Professor of Clinical Pathology/Medical Director, Pathology, ARUP Laboratories/University of Utah School of Medicine
• Janet Jin, PhD, Head, Oncology Assay Development, Roche
• Eugean Jiwanmall, MPH, MBA, Senior Research Analyst, Technology Evaluation and Medical Policy, Independence Blue Cross
• Jennifer C. Jones, MD, PhD, Molecular Immunogenetics & Vaccine Research Section, Vaccine Branch, CCR, NCI
• Rebecca Just, PhD, Visiting Scientist, DNA Support Unit, FBI Laboratory
• Bob Kain, CEO and Cofounder, Luna DNA
• Lisa Kalman, PhD, Senior Advisor for Repository Science, Division of Laboratory Systems, Centers for Disease Control and Prevention
• Ron Kamienchick, MBA, Senior Director, Diagnostics and Personalized Medicine, Digital Health, Teva Pharmaceuticals
• Maria Karasarides, PhD, Executive Director, ImmunoOncology Global Development, Full Medicines Development, Regeneron Pharmaceuticals
• Chris Karlovich, PhD, Associate Director (Contractor), Molecular Characterization Laboratory (MoCha), Leidos BioMedical Research, Inc., Frederick National Laboratory for Cancer Research
• Shumei Kato, MD, Assistant Clinical Professor, Hematology & Oncology, Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center
• Michael Klepser, PharmD, FCCP, Professor, Pharmacy Practice, Ferris State University College of Pharmacy
• Yuval Kluger, PhD, Associate Professor, Pathology, Yale University School of Medicine
• Scott Kopetz, MD, PhD, FACP, Associate Professor, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
• Gerald J. Kost, MD, MS, PhD, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, Pathology and Laboratory Medicine, School of Medicine, University of California, Davis
• Jason Kralj, PhD, Staff Scientist, Complex Microbial Systems Group, Biosystems and Biomaterials Division, Material Measurements Laboratory, NIST
• Alexander Krasnitz, PhD, Associate Professor, Simons Center for Quantitative Biology, Cold Spring Harbor Laboratory
• Carsten Krieg, PhD, Assistant Professor, Microbiology & Immunology, Medical University of South Carolina
• Joseph Krueger, PhD, CSO, Flagship Biosciences
• Amit Kumar, PhD, President and CEO, Anixa Diagnostics
• Marc Ladanyi, MD, William J. Ruane Chair in Molecular Oncology, Molecular Diagnostics Service and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center
• Eric Lai, PhD, Partner, Personalized Science, LLS; Former Senior Vice President, Takeda Pharmaceuticals
• Myla Lai-Goldman, MD, CEO, GeneCentric Therapeutics
• James Landers, PhD, Commonwealth Professor of Chemistry, Professor of Mechanical Engineering, Associate Professor of Pathology, University of Virginia
• Omar Laterza, PhD, DABCC, Executive Director, Molecular Biomarkers and Diagnostics, Merck & Co., Inc.
• Theresa LaVallee, PhD, Head of Translational Medicine, The Parker Institute for Cancer Immunotherapy
• Matthew Lebo, PhD, FACMG, Director, Bioinformatics, Partners Personalized Medicine; Instructor, Pathology, Brigham and Women’s and Harvard Medical School
• Nathan Ledeboer, PhD, Associate Professor of Pathology and Medical Director, Medical College of Wisconsin
• Eunice Lee, PhD, Branch Chief, Molecular Pathology and Cytology Branch, Division of Molecular Genetics and Pathology, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA
• John Leite, PhD, Vice President, Oncology Market Development, Illumina
• Monkol Lek, PhD, Assistant Professor, Genetics, Yale School of Medicine
• Debra G.B. Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine, The University of Vermont Health Network and the Robert Larner, M.D. College of Medicine, University of Vermont
• Kent Lewandrowski, MD, Associate Chief of Pathology, Director, Pathology Laboratories and Molecular Medicine, Massachusetts General Hospital; Professor, Pathology, Harvard Medical School
• J. Leonard Lichtenfeld, MD, MACP, Deputy CMO, American Cancer Society, Inc.
• Stephen E. Lincoln, Head of Scientific Affairs, InVitae
• Xuefeng Liu, MD, Professor, Pathology, Georgetown University
• Roger Longman, CEO, RealEndpoints
• Chang Lu, PhD, Fred W. Bull Professor, Chemical Engineering, Virginia Tech
• Christine Lu, PhD, Associate Professor, Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute
• John Lubniewski, Chief Business Officer, HTG Molecular
• Raja Luthra, PhD, Professor, Hematopathology, The University of Texas MD Anderson Cancer Center
• Hisani Madison, PhD, MPH, Scientific Reviewer, Division of Molecular Genetics and Pathology, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration
• Dario Marchetti, PhD, Director, Biomarker Program, Methodist Hospital, Biomarker Program, Houston Methodist Research Institute
• Bernard L. Marini, PharmD, BCOP, Clinical Pharmacist Specialist, Inpatient Hematology/Oncology, Adjunct Clinical Assistant Professor, Pharmacy, University of Michigan Health System
• Charla Marshall, PhD, Chief, Emerging Technologies Section, Armed Forces DNA Lab
• Christian R. Marshall, PhD, FACMG, Molecular Laboratory Director, Genome Diagnostics, The Hospital for Sick Children
• Kimberly Martin, MD, Chief Clinical Advisor, Women's Health, Natera, Inc.
• Stuart Martin, PhD, Professor, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine
• Gary Martucci, Vice President, National & Strategic Relations at Foundation Medicine
• Charles Mathews, Principal, ClearView Healthcare Partners
• Larissa May, MD, MSPH, MSHS, Professor, Emergency Medicine; Director, Emergency Department Antibiotic Stewardship, University of California Davis
• J. Joseph Melenhorst, PhD, Director, Product Development & Correlative Sciences Laboratories (PDCS); Adjunct Associate Professor, Center for Cellular Immunotherapies, University of Pennsylvania
• Tyler Merkeley, BARDA’s CARB-X Program Manager, Health Scientist, Division of CBRN Countermeasures, BARDA
• Kevin Messacar, MD, Assistant Professor, Pediatrics, University of Colorado/Children’s Hospital Colorado, Section of Infectious Diseases
• Donna A. Messner, PhD, Senior Vice President, Center for Medical Technology Policy, Program Director, Green Park Collaborative
• Wouter Meuleman, PhD, Director, Venture Investments, Illumina Ventures
• Timothy D. Minogue, PhD, Chief, Molecular Diagnostics Department, Diagnostic Systems Division, USAMRIID
• David T. Miyamoto, MD, PhD, Assistant Professor, Radiation Oncology, Harvard Medical School, Center for Cancer Research, Massachusetts General Hospital
• Richard Montagna, PhD, FACB, Senior Vice President, Scientific & Clinical Affairs, Rheonix, Inc.
• Jennifer J.D. Morrissette, PhD, FACMG, Scientific Director, Clinical Cancer Cytogenetics; Clinical Director, Center for Personalized Diagnostics, Department of Pathology, University of Pennsylvania
• Chris Myatt, Founder & CEO, MBio Diagnostics, Inc
• Rakesh Nagarajan, MD, PhD, Chief Biomedical Informatics Officer, PierianDx
• Sunitha Nagrath, PhD, Associate Professor, Chemical Engineering, University of Michigan
• Niven R. Narain, President & CEO, Berg Pharma
• Lee Newcomer, MD, Consultant
• James H. Nichols, PhD, DABCC, FAACC, Professor, Pathology, Microbiology and Immunology; Medical Director, Clinical Chemistry and Point-of-Care Testing, Vanderbilt University School of Medicine
• Angelika Niemz, PhD, Arnold and Mabel Beckman Professor, Keck Graduate Institute
• Brad Nohe, MBA, Head of Lupus, Global Product and Portfolio Strategy, AstraZeneca
• Anne Marie O’Broin-Lennon, MD, PhD, Director, Multidisciplinary Pancreatic Cyst Program; Associate Professor of Medicine, Johns Hopkins University
• Costanza Paoletti, MD, Research Investigator, Internal Medicine, Hematology Oncology, University of Michigan Comprehensive Cancer Center
• Nickolas Papadopoulos, PhD, Professor, Oncology and Pathology; Director, Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions
• Abhijit Patel, MD, PhD, Associate Professor, Therapeutic Radiology, Yale University School of Medicine
• Cloud Paweletz, PhD, Head, Translational Research Laboratory, Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute
• Eric Peters, PhD, Director, Head, Companion Diagnostics, Genentech
• Emanuel Petricoin, PhD, Co-Director, Center for Applied Proteomics and Molecular Medicine, George Mason University
• Jamie Platt, PhD, Managing Director, BRIDGenomics, LLC
• Christopher Polage, MD, MAS, Medical Director, Duke University Health Systems Clinical Microbiology Laboratory; Associate Processor, Duke University Medical Center
• Caroline Popper, MD, President, Popper and Company
• Nader Pourmand, PhD, Professor, Biomolecular Engineering, UC Santa Cruz
• Victoria M. Pratt, PhD, FACMG, Director, Pharmacogenomics and Molecular Genetics Laboratories, Department of Medical and Molecular Genetics, Indiana University School of Medicine (AMP President-Elect)
• Daryl Pritchard, PhD, Senior Vice President, Science Policy, PMC
• Gary W. Procop, MD, Director, Molecular Microbiology, Parasitology, Virology Laboratories; Co-Chair, Enterprise Laboratory Stewardship Committee, Medical Operations; Processor of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic
• Iulian Pruteanu-Malinici, PhD, Biostatistics, Investigator II, Lab Head, Novartis Institutes for BioMedical Research (NIBR)
• Trevor Pugh, PhD, FACMG, Scientist, Princess Margaret Cancer Centre, University Health Network, Assistant Professor, Department of Medical Biophysics, University of Toronto
• Girish Putcha, MD, PhD, Director of Laboratory Science, MolDx, Palmetto GBA
• Ammar Qadan, Vice President, Global Market Access, Illumina
• Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates
• Julie Ramage, National Account Director, Diagnostics, Pfizer Oncology
• Debra Rasmussen, Senior Director, Regulatory Affairs, Johnson & Johnson Company
• Clifford A. Reid, PhD, CEO, Travera
• Alex Reuben, PhD, Postdoctoral Fellow, Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center
• Peggy Robinson, Vice President, Angle PLC
• Ana I. Robles, PhD, Staff Scientist, Laboratory of Human Carcinogenesis, National Cancer Institute
• Jaime Rodriguez-Canales, MD, FEBP, Senior Pathologist, Translational Pathology Laboratory, MedImmune
• Joseph Rubino, PhD, Senior Reimbursement Specialist, Cepheid
• Wendy Rubinstein, MD, PhD, Division Director, Clinical Data Management and Curation, CancerLinQ, LLC, American Society of Clinical Oncology
• Eric Rush, MD, FAAP, FACMG, Clinical Geneticist, Associate Professor of Pediatrics, Pediatrics, Children’s Mercy Kansas City
• Pallavi Sachdev, MPH, PhD, Director, Clinical Pharmacology and Translational Medicine, Oncology, Eisai Inc.
• Ann M. Sakaguchi, MPH, PhD, Specialist, Director, Pacific Emergency Management, Preparedness, Response, Information Network and Training Services (Pacific EMPRINTS), National Disaster Life Support Regional Training Center-Pacific, Anthropology, University of Hawaii, College of Social Sciences
• Marc Samuels, Founder, CEO, ADVI
• David Sans, PhD, MBA, F.A.A.R.M., Managing Director, Healthcare Capital Markets, THINK EQUITY (A Division of Fordham Financial Mgmt., Inc.)
• Avni Santani, PhD, FACMG, Director - Clinical Laboratories, Strategic Partnerships and Innovation, Center for Applied Genomics, Children’s Hospital of Philadelphia; Assistant Professor of Clinical Pathology, Perelman School of Medicine, University of Pennsylvania
• Nasrin Sarafan-Vasseur, PhD, Research Engineer, Genetics, Rouen University Hospital, Inserm
• Carol Saunders, PhD, FACMG, Clinical Laboratory Director, Professor of Pediatric Pathology, Center for Pediatric Genomic Medicine, Children’s Mercy Kansas City
• Danielle Scelfo, Senior Director, Health Policy and Reimbursement, Hologic, Inc.
• Aaron J. Schetter, PhD, Scientific Reviewer, Division of Molecular Genetics and Pathology, CDRH, FDA
• Cecilia Schott, PharmD, MBA, Vice President, Precision Medicine, Global Product & Portfolio Strategy, AstraZeneca
• Amy Schwartz, PhD, Human Centric Design Thought Leader, Health and Consumer Solutions, Battelle
• Nefize Sertac Kip, MD, PhD, Associate Professor, Molecular Oncology, Icahn School of Medicine, Mount Sinai
• Devon J. Shedlock, Vice President, Preclinical Development, Poseida Therapeutics
• Martin Siaw, PhD, MB(ASCP), Technical Consultant, Siaw Consulting
• Heike Sichtig, PhD, Principal Investigator and Team Lead, Microbiology Devices, Center for Devices (CDRH), FDA
• John Simmons, PhD, Director, Translational Science & Diagnostics, Personal Genome Diagnostics
• Anthony Sireci, MD, MSc, Physician Manager, Personalized Genomic Medicine, Assistant Professor of Pathology Columbia University
• Stan Skrzypczak, MBA, Vice President, Corporate Development and Reimbursement, Guardant Health, Inc.
• Tom Slezak, Distinguished Member of the Technical Staff, Global Security Program, Lawrence Livermore National Lab
• Marek Smieja, MD, PhD, Professor, Pathology & Molecular Medicine, McMaster University; Head, Microbiology, Hamilton Regional Laboratory Medicine Program
• Joshua Smith, PhD, Research Staff Member, Translational Systems Biology and Nanobiotechnology, IBM T.J. Watson Research Center
• Steven A. Soper, PhD, Foundation Distinguished Professor, Chemistry, Mechanical Engineering, Cancer Biology, and Bioengineering, University of Kansas
• Lynn R. Sorbara, PhD, Program Director, Cancer Biomarker Research Group, National Cancer Institute
• Nicole D. St. Jean, Director, Precision Medicine, Global Marketing, Oncology Business Unit, AstraZeneca
• Ester Stein, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories
• Michael Steinbaugh, PhD, Research Associate, Biostatistics, Harvard T.H. Chan School of Public Health
• Katie Streicher, Ph.D., Associate Director, Translational Medicine, Medimmune
• Mario Suva, MD, PhD, Assistant Professor, Pathology, Massachusetts General Hospital
• Katherine B. Szarama PhD, Presidential Management Fellow, CMS
• Valerie Taly, PhD, CNRS Research Director (Dr2), Group Leader, Co-Director Ediag Platform, UFR Des Sciences Fondamentales Et Biomedicales, France
• Janis M. Taube, MD, Director, Dermatopathology Division and Fellowship, Associate Professor of Dermatology, Pathology, and Oncology, Johns Hopkins University
• Chwee Teck Lim, PhD, Professor, Mechanobiology Institute, National University of Singapore
• Patrick Terry, CEO, Gray Group Ventures
• Shannon N. Tessier, PhD, Instructor, Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital, Harvard Medical School
• Živana Težak, PhD, Associate Director for Science and Technology, Office of In Vitro Diagnostics and Radiological Health (OIR), CDRH/FDA
• Mya Thomae, Regulatory Advisor
• Peter Tobin, PhD, Chemist, Division of Program Operations and Management, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration
• Dan Todd, Principal, Todd Strategy
• John Truesdell, Senior Director and Life Cycle Lead, FoundationOne CDx, Marketing, Foundation Medicine
• Ephraim L. Tsalik, MD, MHS, PhD, Associate Professor of Medicine, Duke University School of Medicine; Founder, Host Response, Inc.
• Gregory J. Tsongalis, PhD, HCLD, CC, Professor, Pathology; Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT), Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth
• Dana W.Y. Tsui, PhD, Assistant Attending Geneticist; Member, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
• Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Bio
• Katherine Tynan, PhD, Tynan Consulting LLC
• Susan Van Meter, Executive Director, AdvaMedDx
• Siva A. Vanapalli, PhD, Professor, Chemical Engineering, Texas Tech University
• Janaki Veeraraghavan, PhD, Senior Staff Fellow, FDA
• Akos Vertes, PhD, DSc, Professor of Chemistry, Professor of Biochemistry and Molecular Biology, Department of Chemistry, George Washington University
• Christine Vietz, Senior Director, Regulatory Affairs, Foundation Medicine
• Jorge Villacian, MD, CMO, Janssen Diagnostics
• Guiqing (Hank) Wang, MD, PhD, Chief of Labs, Pathology and Clinical Laboratories, Westchester Medical Center & New York Medical College
• Shan X. Wang, PhD, Professor, Materials Science and Engineering, and Electrical Engineering, Stanford University
• John Warren, Senior Director, McDermottPlus Consulting
• Ludmila V. West, New Product Development Lead, Porticos, Inc.
• Karen Whiting, PhD, Global NPD Manager, NPD, BBI Group
• Christopher Williams, Vice President, Business Development, Multiple Myeloma Research Foundation
• Walt Williams, Director, Revenue Optimization & Strategy, Revenue Cycle Services, Quadax
• Ignacio I. Wistuba, MD, Professor & Chair, Department of Translational Molecular Pathology, Anderson Clinical Faculty Chair for Cancer Treatment and Research, UT MD Anderson Cancer Center
• Lawrence J. Worden, Principal, IVD Logix
• Larry K. Wray, PhD, Wray IVD Consulting
• Benjamin Wunsch, PhD, Materials Science & Engineering, Surface Chemist, Staff, Nanobiotechnology, IBM Research, IBM
• Wenming Xiao, PhD, Principle Investigator, Division of Bioinformatics and Biostatistics, NCTR/FDA
• Xiaodong Xiao, PhD, Director, Biologics Discovery, Biologics Lead Discovery, Bristol-Myers Squibb
• Paul Yager, PhD, Professor, Department of Bioengineering, University of Washington
• Roman Yelensky, PhD, Executive Vice President and CTO, Sequencing and Bioinformatics, Gritstone Oncology
• Charles Young, PhD, Principal Professional Staff, Assistant Program Manager, Applied Biology Group, Asymmetric Operations Sector, The Johns Hopkins University Applied Physics Laboratory
• Ian S. Young, MD, PhD, Chief Scientific Advisor, Department of Health (Northern Ireland) and President, Association for Clinical Biochemistry and Laboratory Medicine (ACB), UK
• Min Yu, MD, PhD, Assistant Professor, Stem Cell Biology and Regenerative Medicine Member, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
• Renee Yura, PhD, Director, Precision Medicine and CDx, Celgene
• Ahmet Zehir, PhD, Director, Clinical Bioinformatics, Assistant Attending, Pathology, Memorial Sloan Kettering Cancer Center
• Kang Zhang, MD, PhD, Professor, Human Genetics and Nano-Engineering; Founding Director, Institute for Genomic Medicine, University of California, San Diego
• Justin Zook, PhD, Research Scientist, Genome-Scale Measurements Group, National Institute of Standards and Technology (NIST)

• Youli Zu, MD, PhD, Professor and Endowed Chair in Pathology; Chief, Hematopathology Section; Director, Cancer Pathology Research Lab, Pathology and Genomic Medicine, Houston Methodist Hospital
• Stephan Zuchner, MD, PhD, Professor, Human Genetics, University of Miami